Lipocine (NASDAQ:LPCN – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Lipocine to post earnings of ($0.26) per share and revenue of $2.61 million for the quarter.
Lipocine Trading Up 2.0 %
LPCN stock opened at $3.07 on Wednesday. The stock has a 50-day moving average price of $4.19 and a two-hundred day moving average price of $4.56. Lipocine has a 1 year low of $2.91 and a 1 year high of $11.79. The stock has a market cap of $16.42 million, a PE ratio of -4.04 and a beta of 1.23.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on Lipocine in a research report on Wednesday, February 26th. They issued a “hold” rating on the stock.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Articles
- Five stocks we like better than Lipocine
- The Role Economic Reports Play in a Successful Investment Strategy
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Investing in the High PE Growth Stocks
- Tesla Stock: Finding a Bottom May Take Time
- Growth Stocks: What They Are, What They Are Not
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20211207065857&h=45&w=95&zc=2){kind=logo}
